Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3579455 | 0.98 | EPHX1 (0.50) | SMN1; SMN2EPHX1EPHX2HSD11B1FFAR4 | |
| SCHEMBL7885345 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2EPHX1EPHX2HSD11B1SLC6A1 | |
| SCHEMBL13934478 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2EPHX1EPHX2FFAR4 | |
| SCHEMBL13617466 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2EPHX1EPHX2HSD11B1 | |
| SCHEMBL4822849 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2EPHX1EPHX2HSD11B1 | |
| SCHEMBL7327464 | 0.81 | EPHX1 (0.47) | EPHX1EPHX2 | |
| SCHEMBL18930342 | 0.80 | HSD11B1 (0.54) | SMN1; SMN2EPHX1EPHX2HSD11B1 | |
| SCHEMBL23533551 | 0.80 | KCNH2 (0.51) | EPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL23533426 | 0.80 | GNAO1 (0.47) | EPHX1EPHX2 | |
| SCHEMBL23671734 | 0.79 | SLC6A1 (0.39) | FFAR4SLC6A1GABRA5GABRB2SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| CN-119684140-A | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-115175894-B | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20230348361-A1 | IONIZABLE LIPID COMPOUNDS | METIS TECHBIO CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348361-A1 | IONIZABLE LIPID COMPOUNDS | METIS TECHBIO CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230346702-A1 | LIPID NANOPARTICLES | METIS TECHBIO CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230346702-A1 | LIPID NANOPARTICLES | METIS TECHBIO CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2023207102-A1 | LIPID NANOPARTICLES | Beijing Jitai Pharmaceutical Technology Co., Ltd. (CN) | 2023-11-02 | — | — | WO | disclosed |
| EP-0511222-A1 | DISUBSTITUTED PIPERIDINES AND PYRROLIDINES AS ANTICHOLINERGIC AGENTS. | PFIZER LTD (GB) | 1992-11-04 | — | — | EP | disclosed |
| US-5112825-A | Antirhinoviral heteroamine-substituted pyridazines | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-05-12 | — | — | US | disclosed |
| US-5100893-A | Viricides, effective against picorna virus, durability | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-03-31 | — | — | US | disclosed |
| WO-1991010651-A1 | ANTICHOLINERGIC AGENTS | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | disclosed |
| EP-0435381-A1 | Antipicornaviral pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-03 | — | — | EP | disclosed |
| US-4983614-A | ANTISPASMODIC, ANTIALLERGENIC AND ANTIHISTAMINE AGENTS | LES LABORATOIRES MERAM (FR) | 1991-01-08 | — | — | US | disclosed |
| EP-0398427-A1 | Antirhinoviral pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-11-22 | — | — | EP | disclosed |
| EP-0037713-B1 | NOVEL 1,3-DIHYDRO-1-((1-PIPERIDINYL)ALKYL)-2H-BENZIMIDAZOL-2-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-02-08 | — | — | EP | disclosed |
| EP-0037713-A1 | Novel 1,3-dihydro-1-((1-piperidinyl)alkyl)-2H-benzimidazol-2-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-10-14 | — | — | EP | disclosed |
| US-4254127-A | ANTIEMETIC, NEUROLIPTIC AND ANTICONGESTIVE AGENT | JANSSEN PHARMACEUTICA, N.V. (BE) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | HDAC6, HDAC9, HDAC7 | SMN1; SMN2 2725/4885EPHX1 4497/4885EPHX2 4315/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | SMN1; SMN2 1183/4885EPHX1 1462/4885EPHX2 2733/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | SMN1; SMN2 1417/4885EPHX1 1514/4885EPHX2 2035/4885 |
| US-20230348361-A1 | IONIZABLE LIPID COMPOUNDS | PHOSPHO1, SLC10A1, SLCO4C1 | SMN1; SMN2 824/4885EPHX1 3592/4885EPHX2 4049/4885 |
| US-20230346702-A1 | LIPID NANOPARTICLES | ABCB4, NPC1L1, CHMP4B | SMN1; SMN2 2092/4885EPHX1 1997/4885EPHX2 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.